| Prasugrel: Clinical development and therapeutic application. | |
| | |
MedLine Citation:
|
PMID: 20020231 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Dual antiplatelet therapy with aspirin and clopidogrel is a cornerstone of the management of patients with acute coronary syndromes and following percutaneous coronary intervention. Despite the proven benefits, clear limitations of clopidogrel exist. Prasugrel is a third-generation thienopyridine antiplatelet agent with pharmacologic characteristics that overcome some of the limitations of clopidogrel, but at the expense of increased bleeding. The promising results seen with prasugrel in large, randomized trials led to its recent approval by the US Food and Drug Administration for reducing thrombotic cardiovascular events in patients with acute coronary syndromes managed with percutaneous coronary intervention. This article will review the limitations of standard antiplatelet therapy and discuss the clinical application of prasugrel. |
| | |
Authors:
|
Daniel R Guerra; James E Tcheng |
Publication Detail:
|
Type: Journal Article; Review Date: 2009-12-17 |
Journal Detail:
|
Title: Advances in therapy Volume: 26 ISSN: 1865-8652 ISO Abbreviation: Adv Ther Publication Date: 2009 Nov |
Date Detail:
|
Created Date: 2010-01-21 Completed Date: 2010-03-23 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8611864 Medline TA: Adv Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 999-1011 Citation Subset: T |
Affiliation:
|
Cardiac Study Center, Tacoma, WA 98405, USA. danielreneguerra@yahoo.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Coronary Syndrome
/
complications,
drug therapy* Angioplasty / adverse effects Hemorrhage / chemically induced Humans Piperazines / administration & dosage, adverse effects, therapeutic use* Platelet Aggregation Inhibitors / administration & dosage, adverse effects, therapeutic use* Randomized Controlled Trials as Topic Thiophenes / administration & dosage, adverse effects, therapeutic use* Thrombosis / etiology, prevention & control* Ticlopidine / administration & dosage, adverse effects, analogs & derivatives*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Piperazines; 0/Platelet Aggregation Inhibitors; 0/Thiophenes; 0/prasugrel; 55142-85-3/Ticlopidine; 90055-48-4/clopidogrel |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: An unusual case of transient dermatological reaction to bortezomib in AL amyloidosis.
Next Document: Changes in corneal endothelial cell density in patients with normal-tension glaucoma.